Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to proteasome inhibitors and other targeted therapies in myeloma.

British journal of haematology - 1 Jul 2018

Wallington-Beddoe Craig T, Sobieraj-Teague Magdalena, Kuss Bryone J, Pitson Stuart M

Abstract excerpt

The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the clinical trials evaluating them in combination with other novel and established therapies. Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies are the most well known and studied classes of novel agents targeting myeloma, with histone deacetylase inhibitors, nuclear export inhibitors and several other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Immunologic Factors

Share to Multiple Myeloma

Share to Proteasome Endopeptidase Complex

Share to Proteasome Inhibitors

Share to Ubiquitin

Source

Identifiers

PMID: 29676460
DOI: 10.1111/bjh.15210

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to proteasome inhibitors and other targeted therapies in myeloma.PMID 29676460Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanismsSemantic proximity Read ↗

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Multiple myeloma.Semantic proximity Read ↗

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Biology and therapy of multiple myelomaSemantic proximity Read ↗

Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.